Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
53
NAGE Quote, Financials, Valuation and Earnings
Last price:
$6.71
Seasonality move
:
21.45%
Day range:
$6.43 - $6.60
52-week range:
$5.16 - $14.69
Dividend yield:
0%
P/E ratio:
26.84x
P/S ratio:
4.42x
P/B ratio:
7.37x
Volume:
789.3K
Avg. volume:
794.1K
1-year change:
20.7%
Market cap:
$521.1M
Revenue:
$99.6M
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
$31.1M | $0.02 | 8.86% | -82.94% | $15.80 |
|
CAI
CAI International
|
-- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
LQDA
Liquidia Corp.
|
$19.5M | -$0.35 | 2761.17% | -50.89% | $39.00 |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$19.4M | -$0.38 | 440.82% | -39.26% | $7.00 |
|
TMDX
TransMedics Group, Inc.
|
$144.8M | $0.36 | 28.37% | 94.67% | $144.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
$6.53 | $15.80 | $521.1M | 26.84x | $0.00 | 0% | 4.42x |
|
CAI
CAI International
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$4.91 | $42.50 | $14.9M | -- | $0.00 | 0% | -- |
|
LQDA
Liquidia Corp.
|
$34.53 | $39.00 | $3B | -- | $0.00 | 0% | 42.63x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
$4.26 | $7.00 | $2.2B | -- | $0.00 | 0% | 39.08x |
|
TMDX
TransMedics Group, Inc.
|
$127.67 | $144.73 | $4.4B | 51.57x | $0.00 | 0% | 8.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
4.14% | 1.676 | 0.41% | 3.21x |
|
CAI
CAI International
|
-- | 0.000 | -- | -- |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
LQDA
Liquidia Corp.
|
90.03% | 0.315 | 10.09% | 1.88x |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
7.29% | 1.657 | 3.43% | 4.27x |
|
TMDX
TransMedics Group, Inc.
|
59.39% | 2.406 | 13.56% | 6.86x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NAGE
Niagen Bioscience, Inc.
|
$21.9M | $4.2M | 35.7% | 37.74% | 12.46% | $3.7M |
|
CAI
CAI International
|
-- | -- | -- | -- | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
LQDA
Liquidia Corp.
|
$50.9M | $1.8M | -79.94% | -221.75% | 3.25% | -$10.7M |
|
RXRX
Recursion Pharmaceuticals, Inc.
|
-$22.9M | -$172.2M | -72.69% | -80.23% | -3327.58% | -$117.6M |
|
TMDX
TransMedics Group, Inc.
|
$84.5M | $23.3M | 11.55% | 33.29% | 16.2% | $61.9M |
Niagen Bioscience, Inc. vs. Competitors
-
Which has Higher Returns NAGE or CAI?
CAI International has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of --. Niagen Bioscience, Inc.'s return on equity of 37.74% beat CAI International's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M CAICAI International-- -- -- -
What do Analysts Say About NAGE or CAI?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 141.96%. On the other hand CAI International has an analysts' consensus of -- which suggests that it could fall by --. Given that Niagen Bioscience, Inc. has higher upside potential than CAI International, analysts believe Niagen Bioscience, Inc. is more attractive than CAI International.
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 CAICAI International0 0 0 -
Is NAGE or CAI More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison CAI International has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAGE or CAI?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CAI International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. CAI International pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or CAI?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are larger than CAI International quarterly revenues of --. Niagen Bioscience, Inc.'s net income of $4.6M is higher than CAI International's net income of --. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 26.84x while CAI International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.42x versus -- for CAI International. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.42x 26.84x $34M $4.6M CAICAI International-- -- -- --
-
Which has Higher Returns NAGE or CVM?
CEL-SCI Corp. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of --. Niagen Bioscience, Inc.'s return on equity of 37.74% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About NAGE or CVM?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 141.96%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Niagen Bioscience, Inc., analysts believe CEL-SCI Corp. is more attractive than Niagen Bioscience, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 CVMCEL-SCI Corp.1 0 0 -
Is NAGE or CVM More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock NAGE or CVM?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or CVM?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are larger than CEL-SCI Corp. quarterly revenues of --. Niagen Bioscience, Inc.'s net income of $4.6M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 26.84x while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.42x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.42x 26.84x $34M $4.6M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns NAGE or LQDA?
Liquidia Corp. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of -6.5%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Liquidia Corp.'s return on equity of -221.75%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M LQDALiquidia Corp.93.65% -$0.04 $221.2M -
What do Analysts Say About NAGE or LQDA?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 141.96%. On the other hand Liquidia Corp. has an analysts' consensus of $39.00 which suggests that it could grow by 27.43%. Given that Niagen Bioscience, Inc. has higher upside potential than Liquidia Corp., analysts believe Niagen Bioscience, Inc. is more attractive than Liquidia Corp..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 LQDALiquidia Corp.6 0 1 -
Is NAGE or LQDA More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.777%.
-
Which is a Better Dividend Stock NAGE or LQDA?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or LQDA?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than Liquidia Corp. quarterly revenues of $54.3M. Niagen Bioscience, Inc.'s net income of $4.6M is higher than Liquidia Corp.'s net income of -$3.5M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 26.84x while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.42x versus 42.63x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.42x 26.84x $34M $4.6M LQDALiquidia Corp.42.63x -- $54.3M -$3.5M
-
Which has Higher Returns NAGE or RXRX?
Recursion Pharmaceuticals, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of -3135.32%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M RXRXRecursion Pharmaceuticals, Inc.-442.74% -$0.36 $1.1B -
What do Analysts Say About NAGE or RXRX?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 141.96%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 64.32%. Given that Niagen Bioscience, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than Recursion Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 RXRXRecursion Pharmaceuticals, Inc.1 5 0 -
Is NAGE or RXRX More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NAGE or RXRX?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or RXRX?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Niagen Bioscience, Inc.'s net income of $4.6M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 26.84x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.42x versus 39.08x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.42x 26.84x $34M $4.6M RXRXRecursion Pharmaceuticals, Inc.39.08x -- $5.2M -$162.3M
-
Which has Higher Returns NAGE or TMDX?
TransMedics Group, Inc. has a net margin of 13.47% compared to Niagen Bioscience, Inc.'s net margin of 16.91%. Niagen Bioscience, Inc.'s return on equity of 37.74% beat TransMedics Group, Inc.'s return on equity of 33.29%.
Company Gross Margin Earnings Per Share Invested Capital NAGENiagen Bioscience, Inc.64.52% $0.05 $73.7M TMDXTransMedics Group, Inc.58.74% $0.66 $874.5M -
What do Analysts Say About NAGE or TMDX?
Niagen Bioscience, Inc. has a consensus price target of $15.80, signalling upside risk potential of 141.96%. On the other hand TransMedics Group, Inc. has an analysts' consensus of $144.73 which suggests that it could grow by 13.36%. Given that Niagen Bioscience, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Niagen Bioscience, Inc. is more attractive than TransMedics Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NAGENiagen Bioscience, Inc.5 0 0 TMDXTransMedics Group, Inc.7 3 0 -
Is NAGE or TMDX More Risky?
Niagen Bioscience, Inc. has a beta of 2.308, which suggesting that the stock is 130.829% more volatile than S&P 500. In comparison TransMedics Group, Inc. has a beta of 2.061, suggesting its more volatile than the S&P 500 by 106.067%.
-
Which is a Better Dividend Stock NAGE or TMDX?
Niagen Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Niagen Bioscience, Inc. pays -- of its earnings as a dividend. TransMedics Group, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NAGE or TMDX?
Niagen Bioscience, Inc. quarterly revenues are $34M, which are smaller than TransMedics Group, Inc. quarterly revenues of $143.8M. Niagen Bioscience, Inc.'s net income of $4.6M is lower than TransMedics Group, Inc.'s net income of $24.3M. Notably, Niagen Bioscience, Inc.'s price-to-earnings ratio is 26.84x while TransMedics Group, Inc.'s PE ratio is 51.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Niagen Bioscience, Inc. is 4.42x versus 8.82x for TransMedics Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NAGENiagen Bioscience, Inc.4.42x 26.84x $34M $4.6M TMDXTransMedics Group, Inc.8.82x 51.57x $143.8M $24.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
